Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSEFINA FABIOLA TUR

Allopathic & Osteopathic Physicians General Practice

NPI
1841292695
CMS profile
1212820
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,240.72

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $896.67 4
Food and Beverage $344.05 9

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Eisai Inc. $1,105.47 10
GlaxoSmithKline, LLC. $135.25 3

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSEFINA FABIOLA TUR

NPI 1841292695 · CMS profile ID 1212820

Allopathic & Osteopathic Physicians / General Practice

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841292695?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSEFINA FABIOLA TUR, NPI 1841292695, CMS profile ID 1212820. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841292695?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOSEFINA FABIOLA TUR, NPI 1841292695, CMS profile ID 1212820. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841292695?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOSEFINA FABIOLA TUR, NPI 1841292695, CMS profile ID 1212820, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1841292695?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $1,240.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $6.9511/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670981623 CMS
GlaxoSmithKline, LLC. $6.9408/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671493637 CMS
Eisai Inc. $12.4808/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698080549 CMS
Eisai Inc. $373.3408/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698080551 CMS
Eisai Inc. $439.5908/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698080553 CMS
Eisai Inc. $45.5708/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698080555 CMS
Eisai Inc. $38.1708/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698080557 CMS
Eisai Inc. $50.0008/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698080559 CMS
Eisai Inc. $12.4808/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698080561 CMS
Eisai Inc. $49.9808/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698080563 CMS
Eisai Inc. $24.9908/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698080565 CMS
Eisai Inc. $58.8708/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698080567 CMS
GlaxoSmithKline, LLC. $121.3604/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670279425 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,240.72 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Principal investigator $158,506.76 7
PY2021 Principal investigator $666,042.08 12
PY2020 Principal investigator $1,186,456.26 65
PY2019 Recipient $517.47 7
PY2019 Principal investigator $369,580.16 189

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

196 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eisai Inc. $2,725.00 12/31/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526261
Principal investigator 1 Eisai Inc. $3,875.00 11/26/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526289
Principal investigator 1 Eisai Inc. $1,600.00 11/26/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526291
Principal investigator 1 Eisai Inc. $2,725.00 11/26/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526293
Principal investigator 1 Eisai Inc. $1,125.00 11/26/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526295
Principal investigator 1 Eisai Inc. $1,125.00 11/26/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526297
Principal investigator 1 Eisai Inc. $2,725.00 11/26/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526299
Principal investigator 1 Eisai Inc. $1,600.00 11/26/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526301
Principal investigator 1 Eisai Inc. $3,875.00 11/26/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526303
Principal investigator 1 SANOFI US SERVICES INC. $5,537.30 11/26/2019 Non-covered Recipient Entity
Finlay Medical Research Corp
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691588767
Principal investigator 1 SANOFI US SERVICES INC. $24.48 11/26/2019 Non-covered Recipient Entity
Finlay Medical Research Corp
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691598446
Principal investigator 1 SANOFI US SERVICES INC. $61.20 11/26/2019 Non-covered Recipient Entity
Finlay Medical Research Corp
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691599031
Principal investigator 1 SANOFI US SERVICES INC. $70.38 11/26/2019 Non-covered Recipient Entity
Finlay Medical Research Corp
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691599141
Principal investigator 1 SANOFI US SERVICES INC. $2,243.80 11/26/2019 Non-covered Recipient Entity
Finlay Medical Research Corp
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691599767
Principal investigator 1 SANOFI US SERVICES INC. $4,447.70 11/26/2019 Non-covered Recipient Entity
Finlay Medical Research Corp
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691600093
Principal investigator 1 Eisai Inc. $8,400.00 11/21/2019 Non-covered Recipient Entity
Finlay Medical Research
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 705571171
Principal investigator 1 Eisai Inc. $3,875.00 10/31/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526263
Principal investigator 1 Eisai Inc. $1,600.00 10/31/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526265
Principal investigator 1 Eisai Inc. $3,875.00 10/31/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526267
Principal investigator 1 Eisai Inc. $1,600.00 10/31/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526269
Principal investigator 1 Eisai Inc. $3,875.00 10/31/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526271
Principal investigator 1 Eisai Inc. $1,600.00 10/31/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526273
Principal investigator 1 Eisai Inc. $3,875.00 10/31/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526275
Principal investigator 1 Eisai Inc. $1,600.00 10/31/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526277
Principal investigator 1 Eisai Inc. $3,875.00 10/31/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526279
Principal investigator 1 Eisai Inc. $3,875.00 10/31/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526283
Principal investigator 1 Eisai Inc. $1,600.00 10/31/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526285
Principal investigator 1 Eisai Inc. $4,480.00 10/31/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526287
Principal investigator 1 Eisai Inc. $1,880.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526061
Principal investigator 1 Eisai Inc. $1,115.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526063
Principal investigator 1 Eisai Inc. $1,125.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526065
Principal investigator 1 Eisai Inc. $3,075.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526067
Principal investigator 1 Eisai Inc. $1,125.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526069
Principal investigator 1 Eisai Inc. $3,802.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526071
Principal investigator 1 Eisai Inc. $1,713.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526073
Principal investigator 1 Eisai Inc. $2,025.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526075
Principal investigator 1 Eisai Inc. $2,025.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526077
Principal investigator 1 Eisai Inc. $2,025.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526079
Principal investigator 1 Eisai Inc. $4,480.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526081
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526083
Principal investigator 1 Eisai Inc. $1,713.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526085
Principal investigator 1 Eisai Inc. $1,125.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526087
Principal investigator 1 Eisai Inc. $1,713.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526089
Principal investigator 1 Eisai Inc. $1,125.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526091
Principal investigator 1 Eisai Inc. $1,125.00 10/01/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526093
Principal investigator 1 SANOFI US SERVICES INC. $8,476.40 09/09/2019 Non-covered Recipient Entity
Finlay Medical Research Corp
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691590379
Principal investigator 1 SANOFI US SERVICES INC. $8,476.40 08/12/2019 Non-covered Recipient Entity
Finlay Medical Research Corp
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691586779
Principal investigator 1 SANOFI US SERVICES INC. $61.20 08/12/2019 Non-covered Recipient Entity
Finlay Medical Research Corp
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691591465
Principal investigator 1 SANOFI US SERVICES INC. $15.30 08/12/2019 Non-covered Recipient Entity
Finlay Medical Research Corp
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691591467
Principal investigator 1 SANOFI US SERVICES INC. $6,818.00 07/22/2019 Non-covered Recipient Entity
Finlay Medical Research Corp
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691584163
Principal investigator 1 Eisai Inc. $2,725.00 07/09/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526129
Principal investigator 1 Eisai Inc. $1,600.00 07/09/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526131
Principal investigator 1 Eisai Inc. $1,600.00 07/09/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526133
Principal investigator 1 Eisai Inc. $3,075.00 07/09/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526135
Principal investigator 1 Eisai Inc. $2,625.00 07/09/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526137
Recipient SANOFI US SERVICES INC. $28.95 06/20/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691558987
Recipient SANOFI US SERVICES INC. $45.01 06/20/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691558993
Recipient SANOFI US SERVICES INC. $49.23 06/20/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691558999
Recipient SANOFI US SERVICES INC. $43.83 06/19/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691558977
Recipient SANOFI US SERVICES INC. $99.50 06/19/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691558979
Recipient SANOFI US SERVICES INC. $37.38 06/19/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691558985
Recipient SANOFI US SERVICES INC. $213.57 06/18/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691558841
Principal investigator 1 Eisai Inc. $3,875.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526095
Principal investigator 1 Eisai Inc. $1,125.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526097
Principal investigator 1 Eisai Inc. $4,025.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526099
Principal investigator 1 Eisai Inc. $3,875.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526101
Principal investigator 1 Eisai Inc. $3,875.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526103
Principal investigator 1 Eisai Inc. $3,875.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526105
Principal investigator 1 Eisai Inc. $3,875.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526107
Principal investigator 1 Eisai Inc. $2,725.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526109
Principal investigator 1 Eisai Inc. $1,875.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526111
Principal investigator 1 Eisai Inc. $2,145.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526113
Principal investigator 1 Eisai Inc. $1,725.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526115
Principal investigator 1 Eisai Inc. $3,875.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526117
Principal investigator 1 Eisai Inc. $4,025.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526119
Principal investigator 1 Eisai Inc. $1,600.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526121
Principal investigator 1 Eisai Inc. $3,802.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526123
Principal investigator 1 Eisai Inc. $3,875.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526125
Principal investigator 1 Eisai Inc. $1,600.00 05/30/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526127
Principal investigator 1 Eisai Inc. $1,880.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526139
Principal investigator 1 Eisai Inc. $1,115.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526141
Principal investigator 1 Eisai Inc. $2,075.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526143
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526145
Principal investigator 1 Eisai Inc. $800.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526147
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526149
Principal investigator 1 Eisai Inc. $475.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526151
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526153
Principal investigator 1 Eisai Inc. $1,880.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526155
Principal investigator 1 Eisai Inc. $1,115.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526157
Principal investigator 1 Eisai Inc. $2,075.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526159
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526161
Principal investigator 1 Eisai Inc. $2,075.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526163
Principal investigator 1 Eisai Inc. $800.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526165
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526167
Principal investigator 1 Eisai Inc. $475.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526169
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526171
Principal investigator 1 Eisai Inc. $1,880.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526173
Principal investigator 1 Eisai Inc. $1,115.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526175
Principal investigator 1 Eisai Inc. $2,075.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526177
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526179
Principal investigator 1 Eisai Inc. $800.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526181
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526183
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526185
Principal investigator 1 Eisai Inc. $475.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526187
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526189
Principal investigator 1 Eisai Inc. $800.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526191
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526193
Principal investigator 1 Eisai Inc. $1,600.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526195
Principal investigator 1 Eisai Inc. $3,802.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526197
Principal investigator 1 Eisai Inc. $1,600.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526199
Principal investigator 1 Eisai Inc. $3,802.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526201
Principal investigator 1 Eisai Inc. $1,600.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526203
Principal investigator 1 Eisai Inc. $475.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526205
Principal investigator 1 Eisai Inc. $3,802.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526207
Principal investigator 1 Eisai Inc. $1,992.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526209
Principal investigator 1 Eisai Inc. $1,600.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526211
Principal investigator 1 Eisai Inc. $3,802.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526213
Principal investigator 1 Eisai Inc. $1,125.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526215
Principal investigator 1 Eisai Inc. $4,480.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526217
Principal investigator 1 Eisai Inc. $1,992.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526219
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526221
Principal investigator 1 Eisai Inc. $1,880.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526223
Principal investigator 1 Eisai Inc. $1,115.00 05/07/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526225
Principal investigator 1 SANOFI US SERVICES INC. $7,500.00 04/22/2019 Non-covered Recipient Entity
Finlay Medical Research Corp
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691563133
Principal investigator 1 Eisai Inc. $3,802.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526227
Principal investigator 1 Eisai Inc. $3,325.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526229
Principal investigator 1 Eisai Inc. $4,480.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526231
Principal investigator 1 Eisai Inc. $1,600.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526233
Principal investigator 1 Eisai Inc. $3,802.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526235
Principal investigator 1 Eisai Inc. $4,480.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526237
Principal investigator 1 Eisai Inc. $475.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526239
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526241
Principal investigator 1 Eisai Inc. $800.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526243
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526245
Principal investigator 1 Eisai Inc. $475.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526247
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526249
Principal investigator 1 Eisai Inc. $1,713.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526251
Principal investigator 1 Eisai Inc. $1,125.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526253
Principal investigator 1 Eisai Inc. $800.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526255
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526257
Principal investigator 1 Eisai Inc. $1,600.00 04/02/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526259
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526019
Principal investigator 1 Eisai Inc. $1,880.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526021
Principal investigator 1 Eisai Inc. $1,115.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526023
Principal investigator 1 Eisai Inc. $800.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526025
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526027
Principal investigator 1 Eisai Inc. $2,075.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526029
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526031
Principal investigator 1 Eisai Inc. $1,713.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526033
Principal investigator 1 Eisai Inc. $2,025.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526035
Principal investigator 1 Eisai Inc. $1,992.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526037
Principal investigator 1 Eisai Inc. $3,325.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526039
Principal investigator 1 Eisai Inc. $1,875.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526041
Principal investigator 1 Eisai Inc. $1,600.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526043
Principal investigator 1 Eisai Inc. $3,802.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526045
Principal investigator 1 Eisai Inc. $1,992.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526047
Principal investigator 1 Eisai Inc. $475.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526049
Principal investigator 1 Eisai Inc. $4,480.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526051
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526053
Principal investigator 1 Eisai Inc. $1,880.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526055
Principal investigator 1 Eisai Inc. $1,115.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526057
Principal investigator 1 Eisai Inc. $2,075.00 03/12/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526059
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525973
Principal investigator 1 Eisai Inc. $475.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525975
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525977
Principal investigator 1 Eisai Inc. $1,880.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525979
Principal investigator 1 Eisai Inc. $1,115.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525981
Principal investigator 1 Eisai Inc. $1,880.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525983
Principal investigator 1 Eisai Inc. $1,115.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525985
Principal investigator 1 Eisai Inc. $2,075.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525987
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525989
Principal investigator 1 Eisai Inc. $800.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525991
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525993
Principal investigator 1 Eisai Inc. $475.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525995
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525997
Principal investigator 1 Eisai Inc. $2,025.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525999
Principal investigator 1 Eisai Inc. $2,625.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526001
Principal investigator 1 Eisai Inc. $2,625.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526003
Principal investigator 1 Eisai Inc. $2,625.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526005
Principal investigator 1 Eisai Inc. $2,075.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526007
Principal investigator 1 Eisai Inc. $1,600.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526009
Principal investigator 1 Eisai Inc. $3,802.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526011
Principal investigator 1 Eisai Inc. $1,600.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526013
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526015
Principal investigator 1 Eisai Inc. $800.00 01/24/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702526017
Principal investigator 1 Eisai Inc. $1,880.00 01/03/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525951
Principal investigator 1 Eisai Inc. $1,115.00 01/03/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525953
Principal investigator 1 Eisai Inc. $1,725.00 01/03/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525955
Principal investigator 1 Eisai Inc. $2,075.00 01/03/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525957
Principal investigator 1 Eisai Inc. $75.00 01/03/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525959
Principal investigator 1 Eisai Inc. $1,880.00 01/03/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525961
Principal investigator 1 Eisai Inc. $1,115.00 01/03/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525963
Principal investigator 1 Eisai Inc. $2,075.00 01/03/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525965
Principal investigator 1 Eisai Inc. $75.00 01/03/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525967
Principal investigator 1 Eisai Inc. $1,125.00 01/03/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525969
Principal investigator 1 Eisai Inc. $1,725.00 01/03/2019 Non-covered Recipient Entity
FINLAY MEDICAL RESEARCH CORP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525971